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MTHFR, TS and XRCC1 genetic variants may affect survival
in patients with myelodysplastic syndromes treated with
supportive care or azacitidine
G Visani1,11, F Loscocco1,11, A Ruzzo2, S Galimberti3, F Graziano1, MT Voso4, E Giacomini2, C Finelli5, E Ciabatti3, E Fabiani4, S Barulli1,
A Volpe6, D Magro7, P Piccaluga8, F Fuligni8, M Vignetti9, P Fazi9, A Piciocchi9, E Gabucci1, M Rocchi10, M Magnani2 and A Isidori1,11
We evaluated the impact of genomic polymorphisms in folate-metabolizing, DNA synthesis and DNA repair enzymes on the clinical
outcome of 108 patients with myelodysplastic syndromes (MDS) receiving best supportive care (BSC) or azacitidine. A statistically
signiﬁcant association between methylenetetrahydrofolate reductase (MTHFR) 677T/T, thymidylate synthase (TS) 5′-untranslated
region (UTR) 3RG, TS 3′-UTR − 6 bp/− 6 bp, XRCC1 399G/G genotypes and short survival was found in patients receiving BSC by
multivariate analysis (Po0.001; P= 0.026; P= 0.058; P= 0.024). MTHFR 677T/T, TS 3′-UTR − 6 bp/− 6 bp and XRCC1 399G/G
genotypes were associated with short survival in patients receiving azacitidine by multivariate analysis (Po0.001; P= 0.004;
P= 0.002). We then performed an exploratory analysis to evaluate the effect of the simultaneous presence of multiple adverse
variant genotypes. Interestingly, patients with ⩾ 1 adverse genetic variants had a short survival, independently from their
International Prognostic Scoring System (IPSS) and therapy received. To our knowledge, this is the ﬁrst study showing that
polymorphisms in folate-metabolizing pathway, DNA synthesis and DNA repair genes could inﬂuence survival of MDS patients.
The Pharmacogenomics Journal advance online publication, 5 December 2017; doi:10.1038/tpj.2017.48
INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group of
hematological malignancies characterized by ineffective hemato-
poiesis and risk for progression to acute myeloid leukemia (AML).
Similar to other malignant diseases, myelodysplasia and its
progression to AML is a genomic instability disorder, resulting
from a stepwise accumulation of genetic abnormalities, probably
because of an increased DNA damage burden and/or reduced
ability to deal with the damage.1,2
Folate is an important nutrient required for DNA synthesis and
methylation because it provides one-carbon donor for the
synthesis of de novo purines and pyrimidines, and remethylation
of homocysteine for methylation reaction of protein, DNA and
RNA. Its deﬁciency has been associated with various vascular and
neurological diseases, as well as with diabetes, psoriasis and
malignancies and acute lymphoblastic leukemia.3 Both genetic
stability of the cell and DNA methylation could be modulated by
folate level. An imbalance between entities in folic acid
metabolism can adversely affect nucleotide synthesis, DNA repair
and methylation systems, leading to impairments in chromosome
segregation, abnormal expression of pro-oncogenes and inactiva-
tion of tumor suppressor genes.4 As a consequence, an alteration
in folic acid metabolism could have an effect on DNA repair
efﬁciency and genomic stability.
Thymidylate synthase (TS) catalyzes the conversion of deoxyur-
idine monophosphate to deoxythymidine monophosphate using
5,10-methylenetetrahydrofolate, a substrate of methylenetetra-
hydrofolate reductase (MTHFR) enzyme, during DNA synthesis.
Impairment in the TS enzyme has been associated with
chromosomal damage and fragile site induction.5 The role of
the TS polymorphisms remains unclear and it may inﬂuence TS
mRNA stability in vitro and its expression in vivo.6,7 It has been
shown that TS could be involved in the etiopathogenesis of AML
and chronic myeloid leukemia.5
The base excision repair pathway is responsible for the repair of
little DNA lesions, as single-strand lesions, oxidative damage,
alkylation or methylation. The base excision repair pathway is a
multistep process that requires the activation of several proteins
and the functional polymorphism in these genes may be
responsible for an altered DNA repair capacity.2,8
It is well known that the presence of functional polymorphisms
in genes affects, in general, the respective enzyme activities. As an
example, two known polymorphisms in the MTHFR gene, C677T
and A1298C, lead to a 30–60% reduction in enzyme activity.9–11
Population-based studies have shown an association between
genetic polymorphisms in folate-metabolizing pathway, DNA
synthesis and DNA repair and solid and hematological
diseases.12–21 Some of these studies also showed an association
between speciﬁc polymorphisms and decreased of survival after
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chemotherapy.8 As an example, Kim et al.5 reported that (1)
MTHFR 677TT genotype is associated with a signiﬁcantly increased
risk for adult acute lymphoblastic leukemia, (2) TS polymorphisms
are involved in the etiopathogenesis of AML and (3) both DNA
synthesis and methylation play important roles in the pathogen-
esis of AML and MDS.
The impact of genomic polymorphisms of folate-metabolizing,
DNA synthesis and DNA repair enzymes on risk and clinical
outcome in patients with hematological disease has been
previously reported, but there are no data on MDS. Moreover,
because of the large clinical use of hypomethylating agents that
modulate the methylation of patients with MDS, in the absence of
a marker predictive of response, it sounds scientiﬁcally good to us
to evaluate genetic variants of genes involved not only in the
methylation pathway, but also in important metabolic checkpoints
relevant for DNA synthesis and repair.
Therefore, we conducted a study to examine the relationship
between nine polymorphisms in ﬁve genes (MTHFR, TS, XRCC1,
XRCC3 and APE1) and survival in patients with MDS. We started by
analyzing patients receiving azacitidine, and therefore we studied
the same genetics variants in patients receiving supportive care
only.
MATERIALS AND METHODS
Study population
The study was approved by the reference ethics committee and was
carried out in accordance with the International Conference on
Harmonization Good Clinical Practice Guidelines, the Declaration of
Helsinki (1996) and local regulatory requirements and laws. All patients
signed informed consent before entering the study. The characteristics of
the 108 patients enrolled between September 2009 and March 2015 (age,
diagnosis, International Prognostic Scoring System (IPSS) risk category and
so on) are listed in Table 1.
Genotype analysis
We performed analyses of nine genetic variants, single-nucleotide
polymorphism and variable number tandem repeat on ﬁve genes as
follows: genomic DNA was isolated from 1 ml of peripheral blood by
means of commercially available kit (QIAamp DNA Blood Midi kit, Hilden,
Germany) according to the manufacturer’s instructions. The laboratory
analyses were performed blind to the patients’ treatment and clinical
outcomes. All samples were genotyped for the following polymorphisms:
MTHFR C677T (Ala222Val; rs1801133) and A1298C (Glu429Ala; rs801131),
TS 5′- untranslated region (UTR) (rs183205964 2R/3R and rs 2853542 3R G/
C) and 3′-UTR (rs11280056 − 6 bp/+6T/T bp), XRCC1 Arg194Trp (rs1799782
C/T) and Arg399Glu (rs25487 G/A), XRCC3 Thr241Met (rs861539 C/T) and
APE1 Asp148Glu (rs1130409 T/G).
Polymorphisms were detected by PCR high-resolution melting assay,
restriction fragment length polymorphism of PCR products and PCR-
pyrosequencing assay. PCR conditions and additional details are listed in
Table 2.
The PCR for restriction fragment length polymorphism and pyrosequen-
cing analyses were performed in a volume of 25 μl using 2× PCR Master
Mix kit (Diatheva, Fano, Italy), 25 ng of genomic DNA and 200 nM of each
primer. Primer sequences and preparative PCR conditions are reported in
Table 2. The PCR high-resolution melting assays were performed by using
commercial kits according to the manufacturer’s instructions (Diatheva).22
Statistical analysis
We checked whether the polymorphisms showed any deviations from
Hardy–Weinberg equilibrium. The frequencies of each polymorphism in
the cohort of patients were compared with the general Italian population
(TSI, Tuscany http://www.ensembl.org/info/genome/variation/index.html).
We separately analyzed two groups of patients according to IPSS stage
and therapy administered. The ﬁrst group consisted of 54 patients with
intermediate-2 and high IPSS treated with azacitidine (AZA group),
whereas the second group consisted of 54 patients with low and
intermediate-1 IPSS receiving only best supportive care (BSC group).
Demographic (age, sex), clinical (hemoglobin level, IPSS) and biological
(karyotype) prognostic features were compared across genotypes, using
Pearson’s χ2 tests (for categorical variables) and Mann–Whitney test and
Kruskal–Wallis tests (for continuous variables), where appropriate.
Additive, dominant (major homozygous plus heterozygous vs minor
homozygous) and recessive (major homozygous vs heterozygous plus
minor homozygous) models were applied to detect associations between
genotypes and overall survival (OS). OS was calculated from the data of
diagnosis to last known date alive, or death. The association between the
cumulative probability of OS among genotypes or haplotypes was
calculated according to the Kaplan–Meier method, whereas signiﬁcant
differences between survival curves were evaluated with log-rank test.
Multivariable analysis was performed by stepwise logistic regression
model, describing as the hazard ratio and 95% conﬁdence interval.
Statistical signiﬁcance was set at Po0.05. All statistical testing was done
using Statistical Package for the Social Sciences SPSS version 20 (SPSS,
Chicago, USA).
RESULTS
Genotype frequencies
The genotype frequencies for each polymorphism are presented
in Table 2; they are not signiﬁcantly different than what would be
expected if the population was in Hardy–Weinberg equilibrium.
No statistically signiﬁcant association was found between demo-
graphic, clinical or prognostic features and all the studied
polymorphisms (data not shown). The frequencies of genotypes
identiﬁed in this study were similar to those reported in the TSI
population.
Survival and genotypes
We evaluated the impact of the genetic variants in MTHFR, TS,
XRCC1, XRCC3 and APE1 genes on the survival of the two groups of
MDS patients enrolled in the study.
In univariate analysis, the comparison of genotypes in the BSC
group showed that patients with homozygous MTHFR 677T/T, TS
5′-UTR 3RG, TS 3′-UTR − 6 bp/− 6 bp and XRCC1 399G/G had a
Table 1. Patient baseline characteristics
Characteristic No. %
Age, years
Median (range) 73 (65–89)
Sex
Male 78 72
Female 30 28
Diagnosis (WHO 2008)
RCUD 29 27
RCMD 25 23
RAEB-1 18 17
RAEB-2 36 33
IPSS
Low/Int-1 54 50
Int-2/High 54 50
Laboratory data, median (range)
WBC, × 109/l 3.5× 109/l (0.85–34× 109/l)
Hemoglobin, g dl− 1 9.5 g dl− 1 (5.7–14.7 g dl− 1)
Platelets, × 109/l 82× 109/l (10–481× 109/l)
BM blasts,% 5% (0–19%)
Abbreviations: BM, bone marrow; Int, intermediate; IPSS, International
Prognostic Scoring System; RAEB, refractory anemia with excess blasts;
RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory
cytopenia with unilineage dysplasia; WBC, white blood cell; WHO, World
Health Organization.
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shorter survival when compared with patients with the other
variant (heterozygous plus the other homozygous). Multivariate
stepwise regression model conﬁrmed these genotypes to be
strong independent prognostic factors, signiﬁcantly associated
with short survival (Table 3).
Interestingly, the comparison of genotypes in the AZA group
conﬁrmed that patients with homozygous MTHFR 677T/T, TS
3′-UTR − 6/− 6 and XRCC1 399G/G had a shorter survival when
compared with patients with the other variant (heterozygous plus
the other homozygous) in both univariate and multivariate
analyses (Table 4).
No signiﬁcant association was found between other
enzymatic polymorphisms and MDS subtypes (data not shown).
In particular, we did not observe any effect of adverse
cytogenetics aberration, when tested alone, on survival.
Regarding novel molecular mutations, we did not evaluate
their possible adverse effect on OS due to the fact that this
group of patients was enrolled and treated in a pre-NGS era, and
we do not have residual genetic samples to test molecular
mutations now.
Combination of variant genotypes and survival
We then performed an exploratory analysis to evaluate which
impact could have the simultaneous presence of multiple adverse
variant genotypes on survival in both groups (BSC and AZA
groups). Patients were stratiﬁed according to the number of
adverse genotypes. A strong, negative effect on OS was observed
in patients with multiple adverse genotypes. In the BSC group, the
3-year OS was 33% for patients with ⩾ 2 variant alleles as
compared with 62.5% and 100%, respectively, for those with 2 or
0/1 variant alleles (Figure 1a). The predictive role of the
combination of adverse genotypes on survival was also conﬁrmed
in the AZA group (Figure 1b), suggesting that patients
with a higher number of genetic variants in genes involved
in DNA synthesis, repair and in folate pathway had a short
survival, independently from their IPSS score and therapy
received.
DISCUSSION
MDS have been presumed to be stem cell disorders, and it has
been suspected that the development of MDS results from
accumulation of multiple gene abnormalities, similar to solid
cancer. Elucidation of associations between gene mutations and
clinical phenotypes has advanced rapidly in MDS, whereas the
molecular pathogenesis based on the function of each variant has
not been fully clariﬁed yet.23 Several studies have previously
demonstrated the importance of genetic background on indivi-
dual risk of developing cancer, drug sensitivity and patient
survival.24,25 Moreover, these studies showed that genetic
susceptibility to develop cancer could be the result of the net
effect of multiple single-nucleotide polymorphisms in genes
implicated in various molecular pathways.26 Accordingly, single-
nucleotide polymorphisms could possibility upset the balance
between the most important metabolic pathways and therefore
inﬂuence the development and progression of cancer by
modifying the activity, stability and level of the corresponding
enzymes. Moreover, it has been postulated5 that hematological
malignancies are associated with alterations of plasma folate
levels or DNA repair genes, but the number of patients studied,
difference genotype frequencies and different ethnicities may
inﬂuence the results.
In this study, we demonstrated, for the ﬁrst time, that MTHFR
677TT, TS 3′-UTR − 6/− 6 and XRCC1 399GG genetic polymorph-
isms are associated with statistically signiﬁcant short survival in
MDS patients in both univariate and multivariate analyses. These
ﬁndings are true either for patients with low-risk MDS, receiving
supportive care only, or for high-risk MDS, receiving hypomethy-
lating therapy with azacitidine. This latter ﬁnding, if conﬁrmed in
larger series, could be of particular interest, because so far there is
no validated marker predictive of response to azacitidine, and the
role of global gene-speciﬁc methylation is not well deﬁned.
Starting from this, we then evaluated whether the negative
effect on survival of MTHFR 677TT, TS 3′-UTR − 6/− 6 and XRCC1
399GG genetic polymorphisms could increase when multiple
adverse variants simultaneously occur. When we performed an
exploratory analysis to test this hypothesis, we found that patients
Table 3. Stepwise logistic regression model in the BSC group
Gene Genotype Hazard risk 95% CI for hazard risk lower 95% CI for hazard risk upper P-value
XRCC1 399 [G/G]
versus
[A/G-A/A]
7.072 1.295 38.619 0.024
TS 5′-UTR [3RG/3RG, 3RG/3RC, 2R/3RG] versus
[2R/2R, 2R/3RC, 3RC/3RC]
11.447 1.330 98.544 0.026
TS 3′-UTR [− 6 bp/− 6 bp]
versus
[− 6 bp/+6 bp, +6 bp/+6 bp]
4.653 0.946 22.874 0.058
MTHFR 677 [T/T]
versus
[C/T-C/C]
67.125 6.409 703.081 o0.001
Abbreviations: BSC, best supportive care; CI, conﬁdence interval; TS, thymidylate synthase; UTR, untranslated region.
Table 4. Stepwise logistic regression model in the AZA group
Gene Genotype Hazard risk 95% CI for hazard risk lower 95% CI for hazard risk upper P-value
XRCC1 399 [G/G] versus [A/G-A/A] 5.713 1.904 17.142 0.002
TS 3′-UTR [+6 bp/+6 bp] versus [+6 bp/− 6 bp, − 6 bp/− 6 bp] 0.097 0.019 0.479 0.004
MTHFR 677 [T/T] versus [C/T-C/C] 8.587 2.749 26.828 o0.001
Abbreviations: AZA, azacitidine; CI, conﬁdence interval; TS, thymidylate synthase; UTR, untranslated region.
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with a higher number of variant alleles had a worse survival
outcome (Figure 1a and b).
We know that the two cohorts of patients are not comparable,
and we did not want to directly compare them. However, our
study showed that patients with ⩾ 1 adverse genetic variants had
a short survival, independently from their IPSS score and therapy
received. In other words, even if low-risk patients receiving BSC
only and high-risk patients receiving azacitidine are not compar-
able because of clinical characteristics, IPSS score and therapy
received, the presence of ⩾ 1 adverse genetic variants in any of
these cohorts seems to independently affect survival. Indeed, the
simultaneous presence of similar, adverse genotypes inﬂuences
survival in both cohorts of patients. Last but not least, azacitidine
does not perform well in patients with IPSS intermediate-2 or high
bearing ⩾ 1 adverse genotypes. This ﬁnding, if conﬁrmed in larger
series, should be taken in account in order to avoid toxicity in
patients who have a low probability to respond. On the contrary,
azacitidine should be prospectively tested in patients with IPSS
low or intermediate-1 bearing ⩾ 1 adverse genotypes, who had a
dismal survival with BSC only.
We do not know whether the underlying mechanism of MDS or
its progression to AML could be the result of a defect in one or
more pathways involved in methylation and/or DNA repair. At
present, clinical prognostic scores, such as IPSS, WHO Prognostic
Scoring System (WPSS) or Revised-IPSS (R-IPSS), seem to be the
most powerful tools to predict survival time for MDS patients,
together with adverse mutation of few genes detected with
NGS techniques. Even if we do not have next-generation
sequencing data to evaluate the presence of adverse mutation,
such as ASLX1 and SRSF2, in our cohort of patients, our results
show that MDS patients with one or more unfavorable genotype
(s) in the studied pathways have a worse survival, independently
from their risk score at diagnosis. Therefore, it will be necessary, in
the future, to validate our results and correlate them with the
presence or not of driver mutation together with adverse genetic
polymorphisms.
In any case, a possible explanation for the discrepancy between
survival expected from clinical prognostic score and OS resulting
from the presence of multiple adverse genetic variants could be
attributed to the perturbation of folate and methionine status
because of the presence of polymorphisms in the metabolizing
enzyme genes. Folate is an important nutrient required for DNA
synthesis and methylation, because it provides one-carbon donors
for the synthesis of de novo purines and pyrimidines and
remethylation of homocysteine for methylation reaction of
protein, DNA and RNA. Folate deﬁciency may cause DNA
hypomethylation and pro-oncogene activation and/or uracil
misincorporation during DNA synthesis, leading to catastrophic
DNA repair, DNA strand breakage and chromosome damage. This
process could be powered by the failure of the enzymatic activity
of the enzymes of the DNA synthesis and repair that could lead to
cell death by apoptosis or progression to AML.
Moving to DNA methylation, a well-recognized key regulatory
of gene expression, few studies supported a crucial role of
epigenetic changes in MDS and leukemia biology, as well as a
potential impact in patient outcome.27 Using a supervised
approach, Bullinger et al.27 demonstrated a signiﬁcant association
of altered DNA methylation and patient outcome (good or poor
survival) of AML patients. Moreover, the authors were able to build
a predictive model based on quantitative DNA methylation
patterns.27
However, recent studies reported that there is little relation
between the degree of demethylation following hypomethylating
treatment and hematologic response in patients with MDS.28 In
other words, methylation is not a predictive marker of response to
hypomethylating agents for MDS patients, and therefore we
cannot decide which patient can be a good candidate to receive
these drugs taking only in account the degree of methylation. In
this view, polymorphism in key genes regulating not only the
metabolism of the cell, but also its sensitivity to certain type of
drug, MDS speciﬁc, could represent a novel predictive marker that
surely warrants further studies.
To the best of our knowledge, this is the ﬁrst study showing that
polymorphisms in folate-metabolizing pathway, DNA synthesis
and DNA repair genes could affect survival outcome of patients
with MDS. Additional studies, with a larger sample size, and able
Figure 1. Combined effects of adverse genotypes. (a) Overall survival of myelodysplastic syndrome (MDS) patients with low/intermediate-1
(int-1) International Prognostic Scoring System (IPSS) treated with best supportive care, according to the number of adverse genotypes
simultaneously occurring. (b) Overall Survival of MDS patients with intermediate-2 (int-2)/high-risk IPSS treated with azacitidine, according to
the number of adverse genotypes simultaneously occurring.
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to correlate our pharmacogenomics data with novel next-
generation sequencing data, are warranted. In this view, it is
mandatory to further explore the associations between MTHFR, TS
and XRCC1 genetic polymorphisms and survival of MDS patient
treated with hypomethylating agents.
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